Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced third-quarter 2023 financial results, reporting lower revenues and net income. The company reported worldwide net revenues of $13.92 billion for the September quarter, down 6% on a reported basis, or 5.8% on an operational basis. Net income, adjusted for special items, was $2.95 per share in […]
“Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced third-quarter 2023 financial results, reporting lower revenues and net income. The company reported worldwide net revenues of $13.92 billion for the September quarter, down 6% on a reported basis, or 5.8% on an operational basis. Net income, adjusted for special items, was $2.95 per share in […]
· October 27, 2023
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced third-quarter 2023 financial results, reporting lower revenues and net income.
The company reported worldwide net revenues of $13.92 billion for the September quarter, down 6% on a reported basis, or 5.8% on an operational basis.
Net income, adjusted for special items, was $2.95 per share in Q3, compared to $3.66 per share in the year-ago quarter. On a reported basis, third-quarter profit decreased to $1.79 billion or $1.00 per share from $3.95 billion or $2.21 per share last year.
